Biomea Fusion, Inc.(BMEA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMEA Biomea Fusion, Inc.

交易中 11-09 15:06:32 EST

0.6006

+0.0338

+5.96%

最高0.6186	最低0.5480	成交量49.72万
今开0.5763	昨收0.5668	日振幅12.46%
总市值4,342万	流通市值4,185万	总股本7,230万
成交额29.40万	换手率0.71%	流通股本6,969万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":0.600608,"timestamp":1794254760545,"preClose":0.5668,"halted":0,"volume":497175,"delay":0,"changeRate":0.05964714184897682,"floatShares":69685200,"shares":72299440,"eps":-0.471065,"marketStatus":"交易中","change":0.033808,"latestTime":"11-09 15:06:32 EST","open":0.5763,"high":0.6186,"low":0.548,"amount":294027.32121525,"amplitude":0.124559,"askPrice":0.6125,"askSize":100,"bidPrice":0.6001,"bidSize":144,"shortable":3,"etf":0,"ttmEps":-0.471065,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794258000000},"marketStatusCode":2,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":0.5668,"preHourTrading":{"tag":"盘前","latestPrice":0.5603,"preClose":0.5668,"latestTime":"09:23 EST","volume":2838,"amount":1646.9532684,"timestamp":1794234194111,"change":-0.0065,"changeRate":-0.011468,"amplitude":0.055928},"postHourTrading":{"tag":"盘后","latestPrice":0.5601,"preClose":0.5668,"latestTime":"19:53 EST","volume":19372,"amount":10881.15905,"timestamp":1794012838080,"change":-0.0067,"changeRate":-0.011821,"amplitude":0.052929},"volumeRatio":0.48971,"impliedVol":3.1589,"impliedVolPercentile":0.9323},"requestUrl":"/m/hq/s/BMEA","defaultTab":"news","newsList":[{"id":"2669456741","title":"清洁电器行业推进创新升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669456741","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669456741?lang=zh_cn&edition=full","pubTime":"2026-09-24 12:05","pubTimestamp":1790222700,"startTime":"0","endTime":"0","summary":"近年来，清洁电器产业发展表现亮眼。以洗地机为代表的新品类从无到有、从有到优，走进了千万家庭，中国也由此成为全球清洁电器最大的生产基地和消费市常“产业规模持续壮大的背后，是无数中 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260924/c680249703.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260924/c680249703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BMEA","BK4139","AGIX","BK4585","ARTY","AIPO","QTOC","CHAT","BK4539","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167821259","title":"Biomea Fusion：BMF-650的GLP-131一期临床试验顶线结果预计2026年10月揭晓——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1167821259","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167821259?lang=zh_cn&edition=full","pubTime":"2026-09-23 04:03","pubTimestamp":1790107389,"startTime":"0","endTime":"0","summary":"Biomea Fusion公司今日通过美国证券交易委员会（SEC）提交的文件透露，其候选药物BMF-650所涉及的GLP-131一期临床试验，顶线结果预计将在2026年10月公布。这一时间节点的设定，为投资者和业界观察者提供了明确的预期窗口。值得注意的是，该信息源自公司向监管机构提交的正式文件，反映出其披露的规范性与透明度。围绕BMF-650的研发进展，市场关注度持续升温，而此次SEC文件的更新，则进一步明确了关键里程碑的时间框架。随着试验数据的逐步临近，外部各方或将密切关注这一潜在疗法的安全性与有效性信号，以评估其后续开发路径及商业前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146929021","title":"Biomea Fusion宣布Covalent-211 II期临床试验完成入组：Icovamenib用于胰岛素缺乏型2型糖尿病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1146929021","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146929021?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:02","pubTimestamp":1787569327,"startTime":"0","endTime":"0","summary":"Biomea Fusion今日宣布，其针对Icovamenib在胰岛素缺乏型2型糖尿病患者中的Covalent-211 II期临床试验已圆满完成患者入组工作。作为一家专注于精准医疗的创新型企业，Biomea Fusion正全力推进其核心候选药物Icovamenib的临床开发进程。Icovamenib作为一种共价小分子药物，其独特的作用机制有望为胰岛素缺乏型2型糖尿病患者提供全新的治疗选择。随着入组工作的圆满收官，Biomea Fusion预计将按计划推进后续的数据收集与分析工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101441788","title":"Biomea Fusion宣布Opal研究首例患者完成给药：评估Icovamenib联合司美格鲁肽治疗肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=1101441788","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101441788?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:01","pubTimestamp":1786618885,"startTime":"0","endTime":"0","summary":"Biomea Fusion, Inc. 今日宣布，其Opal临床研究已成功完成首例患者给药。该研究旨在评估Icovamenib与司美格鲁肽联合用药方案在肥胖症治疗中的潜力。这一里程碑事件，标志着公司在该领域的探索迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127399742","title":"Biomea Fusion 扩展 I 期 BMF-650 研究：评估快速单步滴定方案及口服 GLP-1 受体激动剂增强减重潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1127399742","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127399742?lang=zh_cn&edition=full","pubTime":"2026-06-06 07:37","pubTimestamp":1780702634,"startTime":"0","endTime":"0","summary":"Biomea Fusion 公司宣布，将扩展其候选药物 BMF-650 的 I 期临床研究。这项扩展旨在评估一种快速单步滴定方案，并进一步探究该口服 GLP-1 受体激动剂在增强减重方面的潜力。研究设计的调整，意在优化给药策略，以期在安全性和有效性之间取得更佳平衡。此举反映了公司加速推进该口服疗法临床开发的战略意图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184885658","title":"Biomea Fusion公布Icovamenib新临床与转化数据，并宣布扩展其I期BMF-650研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1184885658","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184885658?lang=zh_cn&edition=full","pubTime":"2026-06-06 07:34","pubTimestamp":1780702456,"startTime":"0","endTime":"0","summary":"Biomea Fusion, Inc.  在美国糖尿病协会第86届科学会议上，公布了其创新药物Icovamenib的最新临床与转化数据。与此同时，公司宣布将扩大其正在进行的I期BMF-650研究范围。此次公布的数据涵盖了Icovamenib在临床前及早期临床研究中的关键发现，揭示了其在治疗相关疾病领域的潜力。作为战略调整的一部分，Biomea Fusion决定扩展其BMF-650 I期临床试验。这项研究旨在进一步评估Icovamenib的安全性、耐受性、药代动力学及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BMEA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113853657","title":"Biomea Fusion宣布与莱斯特大学达成研究合作，评估Icovamenib联合司美格鲁肽治疗肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=1113853657","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113853657?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:01","pubTimestamp":1780488087,"startTime":"0","endTime":"0","summary":"Biomea Fusion, Inc. (BMEA) 已与莱斯特大学建立研究合作伙伴关系，双方将共同探索其候选药物Icovamenib与司美格鲁肽联合用于肥胖症治疗的潜力。\n这项合作旨在评估联合用药方案在对抗肥胖及相关代谢疾病方面的效果与机制。通过结合Biomea Fusion在创新疗法开发方面的专长与莱斯特大学在代谢研究领域的深厚学术积累，该研究有望为肥胖症治疗提供新的科学见解和潜在的治疗途径。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BMEA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123103303","title":"Biomea Fusion公布Icovamenib在美国糖尿病协会第86届科学会议上的海报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1123103303","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123103303?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:51","pubTimestamp":1778017886,"startTime":"0","endTime":"0","summary":"Biomea Fusion公司宣布，其研发的Icovamenib将在美国糖尿病协会（ADA）第86届科学会议上进行海报展示。这一重要学术活动将为研究者提供展示最新科研成果的平台。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BMEA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101358661","title":"Biomea Fusion携手美国四大学术中心 基于数据启动二期临床试验规划","url":"https://stock-news.laohu8.com/highlight/detail?id=1101358661","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101358661?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:03","pubTimestamp":1777327395,"startTime":"0","endTime":"0","summary":"生物制药公司Biomea Fusion, Inc.宣布，将联合美国四所顶尖学术医学中心共同推进其二期临床试验计划。此次合作建立在现有临床试验数据的基础上，标志着该公司在创新疗法开发领域迈出关键一步。\n据悉，该项二期临床试验方案旨在进一步验证实验药物的安全性与有效性。通过与多家权威学术机构的协同合作，Biomea Fusion有望加速临床开发进程，为后续研究奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4585","BMEA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188895168","title":"Biomea Fusion公司：Icovamenib总体耐受性良好，52周观察期内未发现新的或非预期的安全性信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1188895168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188895168?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:02","pubTimestamp":1777327333,"startTime":"0","endTime":"0","summary":"Biomea Fusion公司公布的最新临床数据显示，其研究性药物Icovamenib在为期52周的观察期内展现出良好的安全性特征。该药物总体耐受性表现优异，研究过程中未识别出任何新的或非预期的安全性警示信号。\n这项长期观察结果进一步支持了Icovamenib的可耐受性特征，为后续临床开发提供了重要的安全性依据。持续52周的监测数据表明，该药物在延长使用期间保持了稳定的安全性能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129778068","title":"Biomea Fusion公布II期Covalent-112试验52周积极数据：Icovamenib治疗12周后1型糖尿病患者C肽水平持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1129778068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129778068?lang=zh_cn&edition=full","pubTime":"2026-04-28 05:38","pubTimestamp":1777325894,"startTime":"0","endTime":"0","summary":"生物制药公司Biomea Fusion近日发布了其针对1型糖尿病研发的II期临床研究Covalent-112的52周积极结果。数据显示，患者在完成12周Icovamenib治疗后，展现出C肽指标的显著提升，且疗效表现出持久性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BMEA","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518331270","title":"Biomea Fusion, Inc.盘中异动 大幅跳水5.17%报2.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518331270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518331270?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:55","pubTimestamp":1741622139,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时55分，Biomea Fusion, Inc.股票出现波动，股价急速下跌5.17%。截至发稿，该股报2.57美元/股，成交量16.4981万股，换手率0.46%，振幅7.01%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Aeon Biopharma, Inc.、Scisparc Ltd.较为活跃，换手率分别为3662.66%、2664.64%、874.12%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 29/04/2026 、Aeon Biopharma, Inc.、Scisparc Ltd.，振幅分别为88.14%、78.32%、49.87%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310235540a26a5a2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310235540a26a5a2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517880499","title":"Biomea Fusion, Inc.盘中异动 大幅拉升5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517880499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517880499?lang=zh_cn&edition=full","pubTime":"2025-03-05 03:40","pubTimestamp":1741117228,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日03时40分，Biomea Fusion, Inc.股票出现波动，股价快速上涨5.30%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Rapport Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1315.96%、1231.18%、1210.94%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305034028989bf335&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305034028989bf335&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634955","title":"Biomea Fusion, Inc.盘中异动 股价大跌5.02%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634955","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634955?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:43","pubTimestamp":1741013020,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时43分，Biomea Fusion, Inc.股票出现波动，股价大幅下挫5.02%。截至发稿，该股报2.75美元/股，成交量2.8127万股，换手率0.08%，振幅6.57%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224340989a1308&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224340989a1308&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BMEA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514389288","title":"Biomea Fusion, Inc.盘中异动 早盘股价大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514389288?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:14","pubTimestamp":1740669250,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时14分，Biomea Fusion, Inc.股票出现波动，股价急速上涨5.28%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.、Quoin Pharmaceuticals Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为749.56%、111.60%、102.56%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为78.88%、43.51%、34.80%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272314109632bab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272314109632bab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BMEA","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856391","title":"Biomea Fusion, Inc.盘中异动 早盘股价大涨5.23%报2.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856391?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:30","pubTimestamp":1740580226,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时30分，Biomea Fusion, Inc.股票出现波动，股价大幅上涨5.23%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Immunoprecise Antibodies Ltd.、Pyxis Oncology, Inc.、天境生物涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2600.31%、109.73%、82.16%，振幅较大的相关个股有Ocean Biomedical, Inc.、Day One Biopharmaceuticals, Inc.、Os Therapies Incorporated，振幅分别为6.00%、5.59%、4.82%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262230279893aa70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262230279893aa70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4585","BMEA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013080","title":"Biomea Fusion, Inc.盘中异动 早盘急速下挫5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514013080?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:13","pubTimestamp":1740496397,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时13分，Biomea Fusion, Inc.股票出现异动，股价快速下跌5.33%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.80%。其相关个股中，Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为1044.73%、583.93%、538.16%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Gri Bio, Inc.、Silexion Therapeutics Corp，振幅分别为63.01%、56.51%、55.83%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231317abdc88ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231317abdc88ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BMEA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513882720","title":"Biomea Fusion, Inc.盘中异动 快速下挫5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513882720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513882720?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:02","pubTimestamp":1740409373,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时02分，Biomea Fusion, Inc.股票出现波动，股价大幅下挫5.49%。截至发稿，该股报3.27美元/股，成交量8.7011万股，换手率0.24%，振幅6.07%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为156.52%、69.90%、25.47%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230253abdb15a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230253abdb15a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMEA","BK4585","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513210724","title":"Biomea Fusion, Inc.盘中异动 急速下跌5.07%报3.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513210724?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:55","pubTimestamp":1740171326,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时55分，Biomea Fusion, Inc.股票出现波动，股价大幅跳水5.07%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Moolec Science Sa C/Wts 涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为331.32%、257.01%、139.17%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222045526988e2cb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222045526988e2cb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BMEA","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512310165","title":"Biomea Fusion, Inc.盘中异动 早盘股价大涨5.09%报3.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512310165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512310165?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:39","pubTimestamp":1739889564,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时39分，Biomea Fusion, Inc.股票出现异动，股价急速拉升5.09%。截至发稿，该股报3.92美元/股，成交量3.1734万股，换手率0.09%，振幅4.21%。Biomea Fusion, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为297.67%、103.36%、81.72%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Biomea Fusion, Inc.公司简介：Biomea Fusion Inc 是一家处于临床前阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822392496279919&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822392496279919&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4539","BMEA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":-0.1137},{"period":"1month","weight":-0.5706},{"period":"3month","weight":-0.5502},{"period":"6month","weight":-0.6319},{"period":"1year","weight":-0.564},{"period":"ytd","weight":-0.5429}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomea Fusion, Inc.于2017年8月9日根据特拉华州法律注册成立。该公司是一家临床阶段的糖尿病和肥胖症药物公司，专注于开发口服小分子药物。经过战略调整，其核心项目包括用于糖尿病和肥胖症的menin抑制剂icovamenib，以及用于肥胖症的下一代口服GLP-1受体激动剂BMF-650。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.06322},{"month":2,"riseRate":0.4,"avgChangeRate":0.025302},{"month":3,"riseRate":0.4,"avgChangeRate":0.163799},{"month":4,"riseRate":0,"avgChangeRate":-0.156763},{"month":5,"riseRate":0.666667,"avgChangeRate":0.113922},{"month":6,"riseRate":0.5,"avgChangeRate":0.078877},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.050106},{"month":8,"riseRate":0.833333,"avgChangeRate":0.137883},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.045065},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.192244},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.047917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.114655}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Biomea Fusion, Inc.(BMEA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Biomea Fusion, Inc.(BMEA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}